3D-QSAR studies on triazolopiperazine amide inhibitors of dipeptidyl peptidase-IV as anti-diabetic agents

SAR and QSAR in Environmental Research

Volumn 20, Issue 5-6, 2009, Pages 519-535

  Saqib, U ^a   Siddiqi, M I ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

3D QSAR; CoMFA; CoMSIA; Dipeptidyl peptidase IV; Triazolopiperazine amide; Type 2 diabetes mellitus

Indexed keywords

COMPUTATIONAL CHEMISTRY; HYDROGEN BONDS; MOLECULAR GRAPHICS;

3D-QSAR; ANTIDIABETIC; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE-MOLECULAR-SIMILARITY-INDICES ANALYSIS; CONTOUR MAP; DIPEPTIDYL PEPTIDASE; DIPEPTIDYL PEPTIDASE-IV; QSAR STUDIES; TRIAZOLOPIPERAZINE AMIDE; TYPE 2 DIABETES MELLITUS;

AMIDES;

EID: 70649098188     PISSN: 1062936X     EISSN: 1029046X     Source Type: Journal    
DOI: 10.1080/10629360903278677     Document Type: Article

References (27)

1. C.G. Fanelli, F. Porcellati, P. Rossetti, and G.B. Bolli, Glucagon: The effects of its excess and deficiency on insulin action, Nutr. Metab. Cardiovasc. Dis. 16 (2006), pp. S28-S34.
2. D. Elahi, M. McAloon-Dyke, N.K. Fukagawa, G.S. Meneilly, A.L. Sclater, K.L. Minaker, J.F. Habener, and D.K. Andersen, The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects, Regul. Peptides. 51 (1994), pp. 63-74.
3. M.A. Nauck, M.M. Heimesaat, C. Ørskov, J.J. Holst, R. Ebert, and W. Creutzfeldt, Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type II diabetes mellitus, J. Clin. Invest. 91 (1993), pp. 301-307.
4. C.M. Rotella, L. Pala, and E. Mannucci, Glucagon-like peptide 1 (GLP-1) and metabolic diseases, J. Endocrinol. Invest. 28 (2005), pp. 746-758.
5. A.M. Lambeir, C. Durinx, S. Scharpe, and I. de Meester, Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPPIV, Crit. Rev. Clin. Lab. Sci. 40 (2003), pp. 209-294.
6. R. Mentlein, B. Gallwitz, and W.E. Schmidt, Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum, Eur. J. Biochem. 214 (1993), pp. 829-835.
7. R.P. Pauly, H.U. Demuth, F. Rosche, J. Schmidt, H.A. White, F. Lynn, C.H. McIntosh, and R.A. Pederson, Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide, Metabolism 48 (1999), pp. 385-389.
8. B. Balkan, L. Kwasnik, R. Miserendino, J.J. Holst, and X. Li, Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats, Diabetologia. 42 (1999), pp. 1324-1331.
9. B. Ahren, J.J. Holst, H. Martensson, and B. Balkan, Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice, Eur. J. Pharmacol. 404 (2000), pp. 239-245.
10. C.F. Deacon, T.E. Hughes, and J.J. Holst, Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in anesthetized pigs, Diabetes. 47 (1998), pp. 764-769.
11. B. Sudre, P. Broqua, R.B. White, D. Ashworth, D.M. Evans, R. Haigh, J.L. Junien, and M.L. Aubert, Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats, Diabetes 51 (2002), pp. 1461-1469.
12. R.A. Pederson, H.A. White, D. Schlenzig, R.P. Pauly, C.H. McIntosh, and H.U. Demuth, Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isuleucine thiazolidide, Diabetes 47 (1998), pp. 1253-1258.
13. E.B. Villhauer, J.A. Brinkman, G.B. Naderi, B.F. Burkey, B.E. Dunning, P. Kapa, B.L. Mangold, M.E. Russell, and T.E. Hughes, 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties, J. Med. Chem. 46 (2003), pp. 2774-2789.
14. D. Kim, L. Wang, M. Beconi, G.J. Eiermann, M.H. Fisher, H. He, G.J. Hickey, J.E. Kowalchick, B. Leiting, K. Lyons, F. Marsilio, M.E. McCann, R.A. Patel, A. Petrov, G. Scapin, S.B. Patel, R.S. Roy, K.W. Joseph, M.J. Wyvratt, B.B. Zhang, L. Zhu, N.A. Thornberry, and A.E. Weber, (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4] triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes, J. Med. Chem. 48 (2005), pp. 141-151.
15. D.J. Augeri, J.A. Robl, D.A. Betebenner, D.R. Magnin, A. Khanna, J.G. Robertson, A. Wang, L.M. Simpkins, P. Taunk, Q. Huang, S.P. Han, B.A. Offei, M. Cap, L. Xin, L. Tao, E. Tozzo, G.E. Welzel, D.M. Egan, J. Marcinkeviciene, S.Y. Chang, S.A. Biller, M.S. Kirby, R.A. Parker, and L.G. Hamann, Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes, J. Med. Chem. 48 (2005), pp. 5025-5037.
16. B. Ahrén, R. Gomis, E. Standl, D. Mills, and A. Schweizer, Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes, Diab. Care. 27 (2004), pp. 2874-2880.
17. R.D. Cramer, D.E. Patterson, and J.D. Bunce, Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins, J. Am. Chem. Soc. 110 (1988), pp. 5959-5967.
18. G. Klebe and U.J. Abraham, Comparative molecular similarity index analysis (CoMSIA) to study hydrogen-bonding properties and to score combinatorial libraries, J. Comput. Aided. Mol. Des. 13 (1999), pp. 1-10.
19. D. Kim, J.E. Kowalchick, S.D. Edmondson, A. Mastracchio, J. Xu, G.J. Eiermann, B. Leiting, J.K. Wu, K.A.D. Pryor, R.A. Patel, H. He, K.A. Lyons, N.A. Thornberry, and A.E. Weber, Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIATM (sitagliptin phosphate), Bioorg. Med. Chem. Lett. 17 (2007), pp. 3373-3377.
20. J.E. Kowalchick, B. Leiting, K.A.D. Pryor, F. Marsilio, J.K. Wu, H. He, K.A. Lyons, G.J. Eiermann, A. Petrov, G. Scapin, R.A. Patel, N.A. Thornberry, A.E. Weber, and D. Kim, Design, synthesis, and biological evaluation of triazolopiperazine-based b-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors, Bioorg. Med. Chem. Lett. 17 (2007), pp. 5934-5939.
21. 2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results, J. Med. Chem. 38 (1995), pp. 1060-1066.
22. M. Clark, R.D. Cramer III, and N.V. Opdenbosch, Validation of the general purpose tripos 5. 2 force field, J. Comput. Chem. 10 (2004), pp. 982-1012.
23. B.L. Bush and R.B. Nachbar, Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA, J. Comput. Aided. Mol. Des. 7 (1993), pp. 587-619.
24. R.D. Cramer, J.D. Bunce, D.E. Patterson, and I.E. Frank, Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies, Quant. Struct.-Act. Relat. 7 (2006), pp. 18-25.
25. S. Wold, Cross-validation estimation of the number of components in factor and principal components analysis, Technometrics 24 (1978), pp. 397-405.
26. Insight II 2000.1 Program (2000) Accelrys, San Diego, CA.
27. SYBYL Molecular Modeling System Version 7.1 (2005), Tripos Inc., St. Louis, MO.